BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 10942634)

  • 41. Factors associated with viral breakthrough in lamivudine monoprophylaxis of hepatitis B virus recurrence after liver transplantation.
    Chan HL; Chui AK; Lau WY; Chan FK; Wong ML; Tse CH; Rao AR; Wong J; Sung JJ
    J Med Virol; 2002 Oct; 68(2):182-7. PubMed ID: 12210406
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prevalence and profile of mutations associated with lamivudine therapy in Indian patients with chronic hepatitis B in the surface and polymerase genes of hepatitis B virus.
    Wakil SM; Kazim SN; Khan LA; Raisuddin S; Parvez MK; Guptan RC; Thakur V; Hasnain SE; Sarin SK
    J Med Virol; 2002 Nov; 68(3):311-8. PubMed ID: 12226816
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Mechanisms of drug resistance in hepatitis viruses B and C].
    Yotsuyanagi H; Koike K
    Nihon Rinsho; 2007 Feb; 65 Suppl 2 Pt. 1():493-6. PubMed ID: 17455669
    [No Abstract]   [Full Text] [Related]  

  • 44. [Interferon].
    Tamori A; Kawada N
    Nihon Rinsho; 2012 Apr; 70(4):620-4. PubMed ID: 22568143
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hepatitis B virus resistance to antivirals: clinical implications and management.
    Zoulim F
    J Hepatol; 2003; 39 Suppl 1():S133-8. PubMed ID: 14708691
    [No Abstract]   [Full Text] [Related]  

  • 46. [Chronic viral hepatitis caused by B and C virus: diagnostic and therapeutic trends].
    Saracco G; Rizzetto M
    Recenti Prog Med; 1999 Nov; 90(11):595-600. PubMed ID: 10608149
    [No Abstract]   [Full Text] [Related]  

  • 47. Hepatitis B and C virus resistance to antiviral therapies--EASL-AASLD-APASL-ALEH-IASL conference.
    Buti M
    IDrugs; 2008 Apr; 11(4):239-41. PubMed ID: 18379952
    [No Abstract]   [Full Text] [Related]  

  • 48. Food and Drug Administration approves lamivudine for hepatitis B.
    Front Med Biol Eng; 1999; 9(1):95. PubMed ID: 10354913
    [No Abstract]   [Full Text] [Related]  

  • 49. Drug resistance in antiviral treatment for infections with hepatitis B and C viruses.
    Yotsuyanagi H; Koike K
    J Gastroenterol; 2007 May; 42(5):329-35. PubMed ID: 17530355
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A pharmacoeconomic appraisal of therapies for hepatitis B and C.
    Younossi ZM; Temple ME; Shermock KM
    Expert Opin Pharmacother; 2001 Feb; 2(2):205-11. PubMed ID: 11336580
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treatment of chronic viral hepatitis.
    Henrion J
    Acta Clin Belg; 1999 Oct; 54(5):281-8. PubMed ID: 10555386
    [No Abstract]   [Full Text] [Related]  

  • 52. Survival of infantile fulminant hepatitis B and treatment with Lamivudine.
    Laubscher B; Gehri M; Roulet M; Wirth S; Gerner P
    J Pediatr Gastroenterol Nutr; 2005 Apr; 40(4):518-20. PubMed ID: 15795605
    [No Abstract]   [Full Text] [Related]  

  • 53. Clinical implications of lamivudine resistance by HBV.
    Schalm SW
    Lancet; 1997 Jan; 349(9044):3-4. PubMed ID: 8988109
    [No Abstract]   [Full Text] [Related]  

  • 54. [Treatment of liver cirrhosis due to hepatitis B with lamivudine].
    Castellano G; Fernández I; Jiménez C; Solís Herruzo JA
    Gastroenterol Hepatol; 1999 Oct; 22(8):433-4. PubMed ID: 10592680
    [No Abstract]   [Full Text] [Related]  

  • 55. Viral hepatitis at a crossroad.
    Lok AS; Pawlotsky JM
    Gastroenterology; 2012 May; 142(6):1261-3. PubMed ID: 22537431
    [No Abstract]   [Full Text] [Related]  

  • 56. Cell-based and animal models for hepatitis B and C viruses.
    Schinazi RF; Ilan E; Black PL; Yao X; Dagan S
    Antivir Chem Chemother; 1999 May; 10(3):99-114. PubMed ID: 10431609
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Drugs for hepatitis B and C infection].
    Iino S
    Nihon Rinsho; 2007 Feb; 65 Suppl 2 Pt. 1():391-5. PubMed ID: 17455651
    [No Abstract]   [Full Text] [Related]  

  • 58. [Therapy noncompliance in chronic viral hepatitis--standard therapy, prognostic parameters, treatment strategy].
    Hopf U
    Praxis (Bern 1994); 1997 Jan; 86(4):83-5. PubMed ID: 9064723
    [No Abstract]   [Full Text] [Related]  

  • 59. [Hepatitis B: when to use lamivudine?].
    Renner EL
    Schweiz Med Wochenschr; 2000 Jan; 130(1-2):39-41. PubMed ID: 10670046
    [No Abstract]   [Full Text] [Related]  

  • 60. Hepatitis B viral genotypes and lamivudine resistance.
    Kao JH; Liu CJ; Chen DS
    J Hepatol; 2002 Feb; 36(2):303-4. PubMed ID: 11830346
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.